Sinovac Biotech completes Anti-COVID-19 Antibody SA55 Injection study

Sinovac Biotech announced that the company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently. Sinovac’s SA55 Injection, which is intended for the treatment of COVID-19 infections, was approved for clinical trial in China on May 24. The phase I clinical trial has confirmed its preliminary safety profile in 40 healthy adults aged 18 to 65 in China. Preliminary results are anticipated by the year’s end. Their studies underscore the SA55’s efficacy in neutralizing the omicron variant and its sublineages, including BA.5, BF.7, BQ.1.1, XBB.1.5, BA.2.86 and the currently dominant strain, EG.5. Xie noted that SA55 is reportedly the only clinical antibody that SARS-CoV-2 hasn’t escaped.